StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Earnings

Lexeo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.30
-$0.60 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Lexeo Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open––-$0.30Release
Q1 FY2026ended Mar 31, 2026May 11, 2026before the open––-$0.25Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026after the close––-$0.27Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open––-$0.33Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open––-$0.60Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open––-$0.99Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025before the open––-$0.78Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024before the open––-$0.89Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024before the open––-$0.64Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––-$0.77Release
Q4 FY2023ended Dec 31, 2023Mar 11, 2024after the close––-$0.86Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Lexeo Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Lexeo Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Lexeo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. News
  6. Results
  7. Results
  8. Update
  9. Update
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?